AstraZeneca Cost Of Revenue from 2010 to 2024

AZN Stock   10,474  412.00  4.09%   
AstraZeneca PLC's Cost Of Revenue is increasing over the years with slightly volatile fluctuation. Cost Of Revenue is expected to dwindle to about 6.5 B. During the period from 2010 to 2024 AstraZeneca PLC Cost Of Revenue annual values regression line had geometric mean of  5,933,105,766 and mean square error of 5443149.4 T. View All Fundamentals
 
Cost Of Revenue  
First Reported
1995-06-30
Previous Quarter
2.2 B
Current Value
3.1 B
Quarterly Volatility
627.1 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check AstraZeneca PLC financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among AstraZeneca PLC's main balance sheet or income statement drivers, such as Depreciation And Amortization of 5.2 B, Interest Expense of 1.7 B or Total Revenue of 24.2 B, as well as many indicators such as . AstraZeneca financial statements analysis is a perfect complement when working with AstraZeneca PLC Valuation or Volatility modules.
  
This module can also supplement various AstraZeneca PLC Technical models . Check out the analysis of AstraZeneca PLC Correlation against competitors.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in AstraZeneca Stock

AstraZeneca PLC financial ratios help investors to determine whether AstraZeneca Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AstraZeneca with respect to the benefits of owning AstraZeneca PLC security.